FDA Approves AstraZeneca’s Imfinzi for Biliary Tract Cancer Imfinzi, a checkpoint inhibitor developed by AstraZeneca, has been approved by the FDA as the first immunotherapy for biliary tract cancer (BTC), a rare and aggressive form of cancer with few treatment options. Imfinzi (durvalumab) has been approved by ...
Find MoreCereVasc Announces FDA Approval of Second IDE Study of the eShunt® System On August 09, 2022, CereVasc, Inc., a privately held, clinical-stage medical device company developing novel, minimally invasive treatments for neurological diseases, announced that the U.S. Food and Drug Administration (FDA) has approved ...
Find MoreNovartis’ Canakinumab Fails in Phase III Trials for NSCLC Canakinumab's prospects as an anticancer therapy were already dwindling when a third phase III trial in non-small cell lung cancer (NSCLC) failed to reach its objectives. The most recent setback came from the CANOPY-A study, which included patients with N...
Find More[caption id="attachment_3536" align="aligncenter" width="1360"] Lung Cancer Infographic[/caption] Lung cancer is among the leading cause of cancer deaths with the lowest survival rate. Early detection can increase the chances of survival. As November is #LungCancerAwareness Month, we are doing our part by increasin...
Find MoreThe discovery of Cyclin Dependent Kinases (CDKs) is a result of increasing number of cancer cases worldwide. The development of CDKs has changed the paradigm for cancer treatment and it has gradually become an interesting area of research in oncology. The research on CDK inhibitors gained momentum because of the fre...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.